Tag Archives: KAHR Bio

Kahr Cancer Immunotherapy Financing News

BIOTECH

KAHR Bio Announces Strong Topline Phase 2 Results for DSP107 in Combination with Anti-PD-L1 Therapy in Colorectal Cancer
January 9, 2026

Phase 2 data demonstrated 17.5-month median overall survival in advanced, chemo-refractory patients with microsatellite stable...

Read more
This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.
Accept